A multifactorial model for ovarian cancer etiology;Ein multifaktorielles modell zur ätiologie des ovarialkarzinoms

Geburtshilfe und Frauenheilkunde

Volumn 62, Issue 11, 2002, Pages 1060-1068

  Von Georgi, Richard ^a   Munstedt K ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Frauenklinik   (Germany)

Author keywords

3DPOK model; Etiology; Hypothesis; Ovarian carcinoma; Prognosis

Indexed keywords

GONADOTROPIN;

CANCER RESEARCH; CANCER RISK; INFLAMMATION; NEUROENDOCRINOLOGY; NONHUMAN; OVARY CANCER; OVULATION; PATHOGENESIS; PROCESS MODEL; PSYCHOPHYSIOLOGY; REVIEW;

EID: 17744414436     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35974     Document Type: Review

References (130)

1. Ader R, Cohen N, Felton D. Psychoneuroimmunology: Interactions between the nervous system and the immune system. Lancet 1995; 345: 99-103
2. Akhmedkhanov AA, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and risk of epithelial cancer. 32nd Annual Meeting of the Society of Gynecologic Oncologist (SGO). Nashville, Tennessee; March 3-7, 2001
3. Alagoz T, Buller RE, Berman M, Anderson B, Marietta A, DiSaia P. What is a normal CA125 level? Gynecol Oncol 1994; 53: 93-97
4. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland. 3. Erweiterte, Aktualisierte Ausgabe. Saarbrücken: Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, 2002
5. Auersperg N, Wong AST, Choi K-C, Kang SK, Leung PCK. Ovarian surface epithelium: Biology, endocrinology and pathology. Endocr Rev 2001; 22: 255-289
6. Balkwill FR. Re: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer I 2000; 92: 162-163
7. Berchuk A, Carney M. Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997; 54: 541-544
8. Bergquist A, Bruse C, Carlberg M, Carlström K. Interleukin 1β, interleukin-6, and tumor necrosis factor-a in endometriotic tissue and in endometrium. Fertil Steril 2001; 75: 489-495
9. Biondi M. Effects of stress on immune function: An overview. In: Ader E, Felten DL, Cohen N (Eds). Psychoneuroimmunology. Vol. 2. 3rd ed. San Diego, San Francisco, New York, Boston, London, Sydney, Tokyo: Academic Press, 2001: 189-226
10. Biondi M, Picardi A. Psychological stress and neuroendocrine function in humans: The last two decades of research. Psychother Psychosom 1999; 68: 114-150
11. Brinton LA, Hoover RN. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CA, Young RC (Eds). Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott-Raven, 1997: 3-29
12. Buller RE, Skilling JS, Sood AA, Plaxe S, Baergen RN, Lager DJ. Field cancerization: Why late "recurrent" ovarian cancer is not recurrent. Am J Obstet Gynecol 1998; 178: 641-649
13. Butow PN, Hiller JE, Price MA, Thackway SV, Kricker A, Tennat CC. Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer. J Psychosom Res 2000; 49: 169-181
14. Casagrande JT, Louie EW, Pike MC, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet 1979; 2: 170-173
15. Cella DF, Orav EJ, Kornblith AB et al. Socioeconomic status and cancer survival. J Clin Oncol 1991; 9: 1500-1509
16. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW. Hormonal profiles after the menopause. Brit Med J 1976; 2: 784-787
17. Chan YM, Ngan HYS, Yip PSF, Li BYG, Lau OWK, Tang GWK. Psychosocial adjustment in gynecologic cancer survivors: A longitudinal study on risk factors for maladjustment. Gynecol Oncol 2001; 80: 387-394
18. Chiaffarino F, Parazzini F, Negri E et al. Time since last birth and the risk of ovarian cancer. Gynecol Oncol 2001; 81: 233-236
19. Cohen S, Williamson GM. Stress and infectious disease in humans. Psychol Bull 1991; 109: 5-24
20. Conte D, Romanelli F, Fillo S et al. Aspirin inhibits androgen response to chorionic gonadotropin in humans. Am J Physiol-Endoc M 1999; 277: E1032-E1037
21. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 104-107
22. Cramer DW, Welch WR, Hutchison GB, Willett W, Scully RE. Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol 1984; 63: 833-838
23. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer 11983; 71: 717-721
24. Dantzer R, Kelley KW. Stress and immunity: An integrated view of relationships between the brain and the immune system. Life Sci 1989; 44: 1995-2008
25. de la Fuente JR, Rosenbaum AH. Psychoneuroendocrinology. Mayo Clin Proc 1979; 54: 109-118
26. Del Priore G, Robischon K, Phipps WR et al. Risk of ovarian cancer after treatment for infertility. N Engl J Med 1995; 332: 1300-1302
27. Eccles DM, Cranston G, Steel CM, Nakamura Y, Leonard RCF. Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene 1990; 5: 1599-1601
28. Ellsworth LR, Allen HH, Nisker JA. Ovarian function after radical hysterectomy for stage lb carcinoma of the cervix. Am J Obstet Gynecol 1983; 145: 185
29. Erzen M, Rakar S, Klancar B, Syrjänen S. Endometriosis-associated ovarian carcinoma (EAOC): An entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001; 83: 100-108
30. Eysenck HJ. The Biological Basis of Personality. Springfield, Illinois: Charles C. Thomas, 1967
31. Eysenck HJ. Sexualität und Persönlichkeit. Wien: Europaverlag, 1977
32. Eysenck HJ. The respective importance of personality, cigarette smoking and interaction effects for the genesis of cancer and coronary heart disease. Pets Indiv Differ 1988; 9: 453-464
33. Eysenck HJ. Personality and cancer. In: Cooper CL (Ed.). Handbook of Stress, Medicine, and Health. Volume 10. Boca Raton: CRC Press, 1996: 193-215
34. Eysenck HJ, Eysenck MW. Personality and individual differences. A Natural Science Approach. New York, London: Plenum Press, 1985
35. Eysenck HJ, Eysenck SBG. Psychoticism as a Dimension of Personality. London, Sydney, Auckland, Toronto: Hodder Stroughton, 1976
36. Faller H. Krankheitsbewältigung und überlebenszeit bei krebskranken. Psychotherapeut 2001; 46: 20-35
37. Fathalla MF. Incessant ovulation - A factor in ovarian neoplasia? Lancet 1971; 2: 163
38. Frank TS. Testing for hereditary risk of breast and ovarian cancer. Community Genet 2000; 3: 193-197
39. Frentzel-Beyme R, Grossarth-Maticek R. The interaction between risk factors and self-regulation in the development of chronic diseases. Int J Hyg Environ Health 2001; 204: 81-88
40. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998; 25: 305-314
41. Fujimoto J, Hirose R, Sakaguchi H, Tamaya T. Clinical significance of expression of estrogen receptor α and β mRNAs in ovarian cancers. Oncology 2000; 58: 334-341
42. Gertig DM, Hunter DJ, Cramer DW et al. Prospective study of talc use and ovarian cancer. J Natl Cancer 1 2000; 92: 249-252
43. Goldberg JM, Piver MS, Jishi MF, Blumenson L. Age at onset of ovarian cancer in woman with a strong family history of ovarian cancer. Gynecol Oncol 1997; 66: 3-9
44. Green A, Purdie D, Bain C, Siskind V, Webb PM. Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Cause Control 2001; 12: 713-719
45. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA-Cancer J Clin 2001; 51: 15-36
46. Greggi S, Parazzini F, Paratore PP et al. Risk factors for ovarian cancer in central Italy. Gynecol Oncol 2000; 79: 50-54
47. Grossarth-Maticek R, Eysenck HJ, Heeb J, Costa SD, Diel IJ. Interactions of psychosocial and physical risk factors in the causation of mammary cancer, and its prevention through psychological methods of treatment. J Clin Psychol 2000; 56: 33-50
48. Gwin ML, Lee N, Rhodes PH, Layde PM, Rubin G. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989; 43: 559-568
49. Haberland J, Bertz J, Görsch B, Schbn D. Krebsinzidenzschätzung für deutschland mittels log-linearer modelle. Gesundheitswesen 2001; 63: 556-560
50. Harlap S, Olson S, Akhmedkhanov A et al. Epithelial ovarian carcinoma and European birthplace of grandparents. Gynecol Oncol 2001; 81: 25-32
51. Harlow BL, Hartge PA. A review of perineal talc exposure and risk of ovarian cancer. Regul Toxicol Pharm 1995; 21: 254-260
52. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white woman. Collaborative ovarian cancer group. Am J Epidemiol 1992; 136: 1204-1211
53. Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriois in epithelial ovarian cancer. Int J Gynecol Obstet 1997; 59: 245-250
54. Katsnis WA, Shields LBE, Spinnato JA, Gercel-Taylor C, Taylor DD. Immune recognition of endometrial tumor antigens induced by multiparity. Gynecol Oncol 1998; 70: 33-39
55. Kavan MG, Engdahl BE, Kay S. Colon cancer: Personality factors predictive of onset and stage of presentation. J Psychosom Res 1995; 39: 1031-1039
56. Konishi I, Kuroda H, Mandai M. Review: Gonadotropins and development of ovarian cancer. Oncology 1999; 57: 45-48
57. Kreitler S, Levavi H, Bornstein G. Personality factors and cervical premalignancy. Pets Indiv Differ 1996; 21: 883-890
58. Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 1998; 69: 192-196
59. Langdon SP, Smyth JF. Growth factors and ovarian cancer. Endocr Relat Cancer 1998; 5: 283-291
60. Lingeman CH. Environmental factors in the etiology of carcinoma of the human ovary: A review. J Ind Med 1983; 4: 365-379
61. Löffler G, Petrides PE. Biochemie und Pathobiochemie. 6. Korrig. Aufl. Berlin, Heidelberg, New York, Barcelona, Budapest, Hongkong, London, Mailand, Paris, Singapur, Tokio: Springer, 1998
62. Lu JJ, Zheng Y, Kang X et al. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 2000; 79: 158-168
63. Lynch HT, Schuelke GS, Wells IC, Cheng SC, Kimberling WJ, Biscone KA. Hereditary ovarian carcinoma: Biomarker studies. Cancer 1985; 55: 410-415
64. Maes M, Van Bockstaele DR, Van Gastel AV et al. The effects of psychological stress on leukocyte subsets distribution in humans: Evidence of immune activation. Neuropsychobiology 1999; 29: 1-9
65. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000; 7: 85-93
66. Mandai M, Konishi I, Kuroda H et al. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 1997; 33: 1501-1507
67. Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 1998; 81: 283-287
68. Marchetti B, Guarcello G, Triolo G, Morale MC, Farinella Z, Scapagnini U. Luteinizing hormone-releasing hormone (LHRH) as natural messenger in neuro-immune-endocrine communicatio. In: Hadden JW, Masek K, Nistico G (Eds). Interactions Among Central Nervous System, Neuroendocrine and Immune System. Rome, Milan: Pythagora Press, 1989: 127-145
69. Marchetti B, Morale MC, Gallo F et al. The hypothalamo-pituitary-gonadal axis and the immune system. In: Ader E, Felten DL, Cohen N (Eds). Psychoneuroimmunology. Vol. 1. 3rd Ed. San Diego, San Francisco, New York, Boston, London, Sydney, Tokyo: Academic Press, 2001: 362-389
70. McNeilly AS. Suckling and the control of gonadotropin secretion. In: Knobil E, Neill JD (Eds). The Physiology of Reproduction. Vol. 2. 2nd Ed. New York: Raven Press, 1994: 1179-1212
71. Miyazaki M, Nagy A, Schally AV et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer 11997; 89: 1803-1809
72. Modan B, Ron E, Lerner-Geva L et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998; 147: 1038-1042
73. Mosgaard BJ, Lidegaard O, Krüger Kjaer S. Infertility, fertility drugs, and invasive ovarian cancer: A case-control study. Fertil Steril 1997; 67: 1005-1012
74. Mosgaard BJ, Lidegaard O, Krüger Kjaer S, Schou G, Andersen AN. Ovarian stimulation and borderline ovarian tumors: A case-control study. Fertil Steril 1998; 10: 1049-1055
75. Münstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000; 89: 1783-1791
76. Münstedt K, Lange S, Hadji P, von Georgi R. Möglichkeiten der prävention von tumorerkrankungen. Frauenarzt 2001; 42: 1083-1097
77. Murdoch WJ. Proteolytic and cellular death mechanisms in ovulatory ovarian rupture. Biol Signal Recept 2000; 9: 102-114
78. Narod AS, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 424-428
79. Nash MA, Ferrandina G, Gordinier M, Loercher A, Freedman RS. The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 1999; 6: 98-107
80. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer I 1999; 91: 1459-1467
81. O'Leary A. Stress, emotion, and the human immune function. Psychol Bull 1990; 108: 363-382
82. Ördög T, Chen M-D, O'Byrne KT et al. On the mechanism of lactational anovulation in the rhesus monkey. Am J Physiol-Endoc M 1998; 37: 665-676
83. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers - Evidence and hypotheses from epidemiological findings. J Steroid Biochem 2000; 74: 357-364
84. Peterson CM, Jolles CJ, Carrell DT et al. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 1994; 52: 26-30
85. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000; 7: 73-83
86. Piver MS, Baker T, Piedmonte M, Sandecki A. Epidemiology and etiology of ovarian cancer. Semin Oncol 1991; 78: 177-185
87. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: Results of a long-term follow-up study. Fertil Steril 1999; 71: 853-859
88. Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol 2001; 27: 278-281
89. Redd WH, Montgomery GH, DuHamel K. Behavioral intervention for cancer treatment side effects. J Natl Cancer 11001; 93: 810-823
90. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996; 63: 254-257
91. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer 11998; 90: 1774-1786
92. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidem Biomar 1995; 44: 441-451
93. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140: 585-597
94. Rosenberg L, Palmer JR, Rao RS et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidem Biomar 2000; 9: 933-937
95. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331 (22): 771-776
96. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin 2001; 127: 73-79
97. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996; 60: 238-244
98. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer I 1997; 89: 932-938
99. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Nat Cancer I 2002; 94: 32-38
100. Schmale AH, Iker H. Hopelessness as a predictor of cervical cancer. Soc Sci Med 1971; 5: 95-100
101. Schmale AH, Iker HP. The affect of hopelessness and the development of cancer. I. Identification of uterine cervical cancer in woman with atypical cytology. Psychosom Med 1966; 28: 714-721
102. Schneider D, Halperin R, Bukovsky I, Hadas E. Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system. Eur J Gynaecol Oncol 1998; 19: 547-662
103. Schuth W. Zur psychosozialen situation der patientin mit ausgedehntem oder fortgeschrittenem ovarialkarzinom. Onkologie 1984; 78: 6-9
104. Sevelda P, Rosen A, Barrada M, Gober S, Vavra N, Salzer H. 1st die verlaufskontrolle falsch negativer CA-125 serumwerte in der tumornachsorge des ovarialkarzinoms sinnvoll? Gynaekol Runds 1990; 30: 210-211
105. Shields LB, Gercel-Taylor C, Yashar CM et al. Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Invest 1997; 4: 298-304
106. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 1989; 49: 3670-3675
107. Shu XO, Gao YT, Yuan JM et al. Dietary factors and epithelial ovarian cancer. Brit J Cancer 1989; 59: 92-96
108. Shushan A, Paltiel O, Schenker JG. Induction of ovulation and borderline ovarian cancer - The hormonal connection? Eur J Obstet Gyn R B 1999; 85: 71-74
109. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/ neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO 1-11) epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11: 119-129
110. Sklar LS, Anisman H. Stress and cancer. Psychol Bull 1981; 89: 369-406
111. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: An Italian case-control study. Ann Oncol 2000; 11: 1171-1173
112. Taylor DD, Homesley HD, Doellgast GJ. Identification of antigenic components recognized by "membran bound" antibodies from ovarian cancer patients. Am J Reprod Immunol 1991; 15: 369-377
113. Umesaki N, Tanaka T, Miyama M, Mizuno K, Kawamura N, Ogita S. Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist. Gynecol Obstet Invest 1999; 48: 66-68
114. Van den Berghe H, Dal Cin P. Some genetic aspects of ovarian tumors. Eur J Obstet Gyn R B 1998; 81: 283-287
115. Van Leeuwen FE, Rookus MA. The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. Eur J Cancer Clin On 1989; 25: 1961-1972
116. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354: 1586-1590
117. Vessey M, Metcalfe A, Wells C, Mcpherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J 1987; 294: 1518-1520
118. von Georgi R, Schubert K, Franke FE, Münstedt K. Auswirkungen soziomedizinischer risikofaktoren auf den verlauf des ovarialkarzinoms. Dtsch Med Wochenschr 2002; 127: 2001-2005
119. Webb PM, Bain CJ, Purdie DM, Harvey PWJ, Green A. Milk consumption, galactose metabolism and ovarian cancer (Australia). Cancer Cause Control 1998; 9: 637-644
120. Weiss NS, Harlow BL. Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer? Am J Epidemiol 1989; 124: 856
121. Whiteman DC, Murphy MFG, Cook LS et al. Multiple births and risk of epithelial ovarian cancer. J Natl Cancer 12000; 92: 1172-1177
122. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white woman. Collaborative ovarian cancer group. Am J Epidemiol 1992; 136: 1184-1203
123. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative ovarian cancer group. Am J Epidemiol 1992; 136: 1212-1220
124. Whittemore AS, Harris R, Itnyre J, Halpern J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. I. Methods. Collaborative ovarian cancer group. Am J Epidemiol 1992; 136: 1175-1183
125. Wise PM. Neuroendocrine modulation of the "menopause": Insights into the aging brain. Am J Physiol-Endoc M 1999; 277: 965-970
126. Wong C, Hempling RE, Piver MS, Natarajan N, Mettlin CJ. Perineal talc exposure and subsequent epithelial ovarian cancer: A case-control study. Obstet Gynecol 1999, 93: 372-376
127. Wu ML, Whittemore AS, Paffenbarger RS et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988; 128: 1216-1227
128. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer I 2000; 92: 1472-1489
129. Zheng W, Lu JJ, Luo F et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000; 76: 80-88
130. Zuckermann M. Psychobiology of Personality. New York, Port Chester, Melbourne, Sydney: Cambridge University Press, 1991